Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1437

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 1437
---
 31, 2024, our Company’s internal
control over financial reporting was adequate in material aspects. 

93

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

ITEM
9B. OTHER INFORMATION

During
the three months ended December 31, 2024, no director or officer of the Company adopted, modified, or terminated a “Rule 10b5-1
trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation
S-K.4

ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not
applicable.

PART
III

ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Officers
and Directors

The
following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held
by each. Our Board of Directors elects our executive officers annually by majority vote. Each director’s term continues until his
or her successor is elected or qualified at the next annual meeting, unless such director earlier resigns or is removed. In addition,
the following table sets forth the names and ages of the members of our Science Advisory Board.

    Name
     
    Age 
     
    Position
  
    Executive
    Officers and Directors:

    Christer
    Rosén
     
    73
     
    Chairman
    of Board, Chief Executive Officer and Director
  
    Saleem
    Elmasri
     
    39
     
    Chief
    Financial Officer and Secretary
  
    Marshall
    Hayward, Ph.D.
     
    70
     
    Chief
    Scientific Officer and Director
  
    Alexander
    Rosén
     
    34
     
    Chief
    Administrative Officer
  
    Alison
    D. Silva
     
    46
     
    President,
    Chief Business Officer, and Director
  
    Nicholas
    H. Hemmerly
     
    42
     
    Independent